T1	p 98 191	lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome .
T2	p 601 645	patients with mixed dyslipidaemia and MetS .
T3	p 668 848	randomised patients with low-density lipoprotein cholesterol ( LDL-C ) > 160 and TG > 200 mg/dl to rosuvastatin monotherapy 40 mg/day ( R group , n = 30 ) or rosuvastatin 10 mg/day
T4	p 858 878	with fenofibrate 200
T5	p 891 905	group , n = 30
T6	i 16 43	rosuvastatin monotherapy or
T7	i 47 94	combination with fenofibrate or ?-3 fatty acids
T8	i 98 121	lipoprotein subfraction
T9	i 468 492	rosuvastatin monotherapy
T10	i 514 558	combined with fenofibrate or ?-3 fatty acids
T11	i 705 716	lipoprotein
T12	i 767 801	rosuvastatin monotherapy 40 mg/day
T13	i 804 805	R
T14	i 823 945	or rosuvastatin 10 mg/day combined with fenofibrate 200 mg/day ( RF group , n = 30 ) or ?-3 fatty acids 2 g/day ( R? group
T15	i 1048 1050	RF
T16	i 1182 1196	polyacrylamide
T17	i 1201 1222	gel electrophoresis .
T18	i 1448 1450	R?
T19	o 98 129	lipoprotein subfraction profile
T20	o 210 230	triglycerides ( TG )
T21	o 233 296	decreased high-density lipoprotein cholesterol ( HDL-C ) levels
T22	o 717 728	cholesterol
T23	o 1132 1163	lipoprotein subfraction profile
T24	o 1235 1248	mean LDL size
T25	o 1314 1331	prominent with RF
T26	o 1388 1416	hypotriglyceridemic capacity
T27	o 1466 1493	in insulin resistance by RF
T28	o 1516 1554	RF significantly raised HDL-C levels (
T29	o 1595 1672	cholesterol of small HDL particles . The cholesterol of larger HDL subclasses
T30	o 1750 1768	mean LDL size ; RF
T31	o 1851 1872	subfraction profile .